Navigation Links
Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia
Date:6/17/2009

OSLO, Norway, June 17 /PRNewswire-FirstCall/ --

- New Investigational Drug Also Shown to Improve Remission Rates and Reduce Short-Term Mortality Compared to Previous Treatments

Clavis Pharma ASA (OSE: CLAVIS) today announces positive final results from a Phase II trial of its novel investigational cancer drug, elacytarabine (CP-4055), in patients with late-stage acute myeloid leukaemia (AML). In the trial, elacytarabine showed statistically significant superior efficacy compared to published clinical data for late-stage AML. Based on these encouraging results an elacytarabine registration study is being planned.

    Key results compared to published clinical data:

    - Median survival three times longer (5.5 months vs. 1.5 months)
    - Remission rate significantly increased (15% vs 2.5%, p<0.0001)
    - Well tolerated - short-term mortality substantially lower (13 per
      cent vs. 25 per cent)

Elacytarabine is a novel cytotoxic agent being developed by Clavis Pharma for the treatment of hematologic cancers and solid tumors, especially those resistant to existing agents. One particularly difficult-to-treat patient group is late-stage acute myeloid leukaemia (AML) patients who have failed two previous therapeutic regimens. There is currently no standard therapy available for these patients and life expectancy is very short. It is in this patient group that Clavis Pharma has evaluated the safety and efficacy of elacytarabine.

Extended survival, improved remissions

In the Phase II study, 61 patients with late stage AML who failed to respond or relapsed after two separate rounds of treatments received third-line therapy (also called second salvage) with intravenous elacytarabine. The response to treatment was compared with a detailed historical outcome analysis of 594 similar second salvage AML patients, who were treated at the MD Anderson C
'/>"/>

SOURCE Clavis Pharma ASA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... James Sherley says he has been working towards ... since his days as a principal investigator at the Fox ... Sherley founded the ASCTC as a new Boston biotech ... property developed in Sherley’s research over the years since FCCC, ... (MIT), and more recently as a senior scientist at the ...
(Date:10/30/2014)... , Oct. 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... announced that management will present a company overview at the ... a.m. ET in Boston, MA. ... on the "Investors & Media" section of the Company,s website, ... Isis website within 48 hours and will be archived for ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 Ryan Carfley ... this month to sit down with Bryan Hamilton, the publisher ... Solutions to discuss talent in the Research Triangle region of ... that were highlighted at the roundtable include the role ... the significance of work/life balance and the unique role that ...
(Date:10/27/2014)... The “Molecular Diagnostic Market by ... INAAT, DNA Sequencing), End User (Hospital, Laboratories), & ... Forecast to 2018” provides a detailed overview of ... trends, and strategies impacting the global molecular diagnostics ... the revenue and share analysis. , The global ...
Breaking Biology Technology:Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5
... NEW YORK, March 9, 2011 Reportlinker.com announces ... in its catalogue: World Market ... and What,s Not, The ... predictions made about the molecular diagnostics but to ...
... 2011 SPX Corporation (NYSE: SPW ) ... B.W. Murdoch Ltd, a leading engineering company supplying processing ... is based in Auckland, New Zealand. Terms of the ... has decades of experience in the New Zealand dairy, ...
... 2011 AccessClosure, Inc., the U.S. market segment ... from the first published study* (Journal of NeuroInterventional ... different vascular closure devices (VCD) as the primary ... the discomfort associated with the Mynx 5F Vascular ...
Cached Biology Technology:Reportlinker Adds World Market for Molecular Diagnostics: Potential and Reality, What's Hot and What's Not , The 2Reportlinker Adds World Market for Molecular Diagnostics: Potential and Reality, What's Hot and What's Not , The 3SPX Announces Acquisition of B.W. Murdoch Ltd, Broadening Process Engineering and Project Management Capabilities in New Zealand and the Asia Pacific Region 2Significant Reduction in Pain With the Mynx Vascular Closure Device Versus Angio-Seal Device 2Significant Reduction in Pain With the Mynx Vascular Closure Device Versus Angio-Seal Device 3
(Date:10/28/2014)... of the tragic realities of cancer is that ... toxic and their effectiveness varies unpredictably from patient ... poised to change this reality by rapidly assessing ... an individual,s cancer before chemotherapy begins. , A ... by Assistant Professor Melissa Skala has developed the ...
(Date:10/28/2014)... announced awards to expand the Office of Rare ... Advancing Translational Sciences (ORDR-NCATS) collaborative Rare Diseases Clinical ... scientists at 22 consortia will work with 98 ... investigate new treatments for patients with rare diseases. ... in fiscal 2014 funding from NIH. , Rett ...
(Date:10/28/2014)... be building a hybrid micro-grid which will integrate ... in the region, the hybrid micro-grid will test ... diesel, storage and power-to-gas technologies, and ensure these ... built under the new Renewable Energy Integration Demonstrator- ... located offshore at Semakau Landfill and is expected ...
Breaking Biology News(10 mins):Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3NTU to build region's first renewable energy integration demonstration micro-grid 2NTU to build region's first renewable energy integration demonstration micro-grid 3
... all the genetic sequences in living organisms, has leaned ... the blueprint, unfortunately, has been unintelligible, with no good ... link genomic features to cell function. , A national ... non-profit research center, and Pacific Northwest National Laboratory (PNNL), ...
... Medicine have identified a link between a critical cancer ... be expressed in a number of EBV-associated cancers. Their ... human B cells from the immune system into cancerous ... , Erle S. Robertson, PhD, Associate Professor of Microbiology ...
... target in their fight against a dangerous bacterium that ... implants such as catheters, artificial joints and heart valves. ... epidermidis has, for the first time, been shown to ... that would otherwise kill the bacteria, according to scientists ...
Cached Biology News:Fleshing out the genome 2Defensins neutralize anthrax toxin 2Substance protects resilient staph bacteria 2
Concentration: 1mg/ml. Antigen: Propidium Iodide ...
Anti-Mouse Qa.m7, Ascites (Clone 5035-50.1) (mouse IgM)...
Barcoded Slides, 5 Packs of 5 Slides (25/Case)...
Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...
Biology Products: